Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zealand Pharma
With
Parexel
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female participants with body mass index (BMI) ≥27.0 kg/m2.
Diagnosed with type 2 diabetes ≥180 days prior to the day of screening.
Treated with metformin with or without sodium-glucose cotransporter 2 inhibitors. Treatment should be stable (same drug\[s\], dose, and dosing frequency) for at least 90 days prior to screening.
You may not be if
Severe hypoglycemia within 6 months prior to screening or history of hypoglycemia unawareness.
Receipt of any other glucose-lowering drug than those listed in the inclusion criterion within 90 days prior to screening.
A self-reported change in body weight \>5% within 90 days prior to screening, irrespective of medical records.
Treatment with any medication (prescribed or over-the-counter) or alternative remedies (herbal or nutritional supplements) intended to promote weight loss within 90 days prior to screening.
Previous or planned (during the trial period) obesity treatment with surgery or a body weight loss device. However, liposuction or surgical removal of fat depots more than 1 year prior to screening or device-based interventions (e.g., sleeve, banding, or similar) that have been removed more than 6 months prior to screening, are allowed.
Obesity due to endocrine disorders or genetic syndromes.
Clareo Health | Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
